Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar 22:11:1133472.
doi: 10.3389/fcell.2023.1133472. eCollection 2023.

Targeting the BRCA1/ 2 deficient cancer with PARP inhibitors: Clinical outcomes and mechanistic insights

Ashwin Ragupathi  1 , Manrose Singh  1 , Alexis M Perez  1 , Dong Zhang  1
Affiliations
Review

Targeting the BRCA1/ 2 deficient cancer with PARP inhibitors: Clinical outcomes and mechanistic insights

Ashwin Ragupathi et al. Front Cell Dev Biol. .

Abstract

BRCA1 and BRCA2 play a critical role in a variety of molecular processes related to DNA metabolism, including homologous recombination and mediating the replication stress response. Individuals with mutations in the BRCA1 and BRCA2 (BRCA1/2) genes have a significantly higher risk of developing various types of cancers, especially cancers of the breast, ovary, pancreas, and prostate. Currently, the Food and Drug Administration (FDA) has approved four PARP inhibitors (PARPi) to treat cancers with BRCA1/2 mutations. In this review, we will first summarize the clinical outcomes of the four FDA-approved PARPi in treating BRCA1/2 deficient cancers. We will then discuss evidence supporting the hypothesis that the cytotoxic effect of PARPi is likely due to inducing excessive replication stress at the difficult-to-replicate (DTR) genomic regions in BRCA1/2 mutated tumors. Finally, we will discuss the ongoing preclinical and clinical studies on how to combine the PARPi with immuno-oncology drugs to further improve clinical outcomes.

Keywords: BRCA1 and BRCA2; PARP inhibitors; PARP1; breast cancer; ovarian cancer; pancreatic cancer; prostate cancer; synthetic lethality.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Diagrams of the four difficult-to-replicate (DTR) loci in human genomes: telomeres (A), common fragile sites (B), centromeres (C), and rDNA loci (D).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Abida W., Patnaik A., Campbell D., Shapiro J., Bryce A. H., McDermott R., et al. (2020). Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration. J. Clin. Oncol. 38, 3763–3772. 10.1200/JCO.20.01035 - DOI - PMC - PubMed
    1. Anscher M. S., Chang E., Gao X., Gong Y., Weinstock C., Bloomquist E., et al. (2021). FDA approval summary: Rucaparib for the treatment of patients with deleterious BRCA-mutated metastatic castrate-resistant prostate cancer. Oncologist 26, 139–146. 10.1002/onco.13585 - DOI - PMC - PubMed
    1. Arlt M. F., Xu B., Durkin S. G., Casper A. M., Kastan M. B., Glover T. W. (2004). BRCA1 is required for common-fragile-site stability via its G2/M checkpoint function. Mol. Cell Biol. 24, 6701–6709. 10.1128/MCB.24.15.6701-6709.2004 - DOI - PMC - PubMed
    1. Arora S., Balasubramaniam S., Zhang H., Berman T., Narayan P., Suzman D., et al. (2021). FDA approval summary: Olaparib monotherapy or in combination with bevacizumab for the maintenance treatment of patients with advanced ovarian cancer. Oncologist 26, e164–e172. 10.1002/onco.13551 - DOI - PMC - PubMed
    1. Azzalin C. M., Reichenbach P., Khoriauli L., Giulotto E., Lingner J. (2007). Telomeric repeat containing RNA and RNA surveillance factors at mammalian chromosome ends. Science 318, 798–801. 10.1126/science.1147182 - DOI - PubMed